Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed full pipeline small index

Candidiasis: full-pipeline trial registry

A small indexed set (8 trials) with no open enrollment listed right now.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · none currently recruiting · #2,176 of 28,707 conditions by registered trial count

Candidiasis: 8 US clinical trials tracked, none currently recruiting.

Candidiasis is the subject of 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 4 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 3 of these trials.

Enrollment posture brief

Registry condition candidiasis

OPEN 0 | RECR 0% | LATE 4 | EARLY 4 | RANK #2176 | SPON 3

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Activity, Motor75%Achalasia50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%Candidiasis (this)0%
Open-enrollment share among volume-matched conditions near Candidiasis

Candidiasis has no open enrollment in this registry pull (8 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Candidiasis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Candidiasis is recruiting below its size-band peers.

    0 of 8 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Candidiasis research.

    National Institute of Allergy and Infectious Diseases (NIAID) accounts for 3 of 8 trials (37.5%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical Candidiasis enrolment sits around 300 participants.

    Median target enrolment is 300 among the 8 trials that report a genuine target (sentinel values excluded). 1 of those (12.5%) plan for fewer than 100 participants.

  4. Candidiasis research is mostly interventional.

    8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 22Phase 33Phase 41

Indexed trials (enrollment closed)

8 total, page 1 of 1

COMPLETED Phase 3 611 participants

Study of Micafungin in Patients With Invasive Candidiasis or Candidemia

Astellas Pharma

NCT00105144

COMPLETED Phase 4 500 participants

Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00001107

COMPLETED Phase 3 362 participants

Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight

Daniel Benjamin

NCT00734539

COMPLETED Phase 3 300 participants

An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections

National Cancer Institute (NCI)

NCT00001810

COMPLETED Phase 2 234 participants

Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women

National Institute of Allergy and Infectious Diseases (NIAID)

NCT01230814

COMPLETED Phase 1 164 participants

Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine

NovaDigm Therapeutics

NCT01447407

COMPLETED Phase 2 120 participants

The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.

Pfizer

NCT00037219

COMPLETED Phase 1 24 participants

A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00000788

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 2
Phase 3 3
Phase 4 1

Named interventions

Most-linked intervention names on Candidiasis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Fluconazole Drug
2 trials
Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate) Drug
1 trials
NDV-3 vaccine without alum ID Biological
1 trials
Placebo with alum IM Biological
1 trials
NDV-3 vaccine without alum IM Biological
1 trials
NDV-3 vaccine with alum IM Biological
1 trials
Anidulafungin, VER002 Drug
1 trials
AmBisome Drug
1 trials

US sites by state

Facility locations filed on Candidiasis trials. A trial with sites in several states counts in each.

Alabama 4 trials
New York 2 trials
Indiana 2 trials
Florida 2 trials
California 2 trials
Arkansas 2 trials
Pennsylvania 1 trials
Nevada 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Candidiasis page

8 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Candidiasis condition card totals 8 registered trials; most-linked intervention Fluconazole; top US site state Alabama. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.